Injectable preparation

A gel composition suitable for the treatment of a human patient comprising

• a poorly soluble drug which is aripiprazole or a salt thereof, or 7-[4-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)butoxy]-1H-quinolin-2-one or a salt thereof,
• water, and
• a suspending agent
• wherein the suspending agent contains polyvinylpyrrolidone, polyethylene glycol, and carboxymethyl cellulose or a salt thereof,
• the poorly soluble drug has a mean primary particle diameter of 0.5 to 30 μm and is contained in a concentration of 300 mg/mL,
• K value of polyvinylpyrrolidone is 17, and the concentration of polyvinylpyrrolidone is 4 mg/mL,
• the polyethylene glycol is polyethylene glycol 400, and the concentration of polyethylene glycol is 1 mg/mL,
• the concentration of carboxymethyl cellulose or a salt thereof is 5 mg/mL, and the composition is in gel form for storage and forms a sol when subjected to an impact.

A sustained release injectable preparation suitable for the treatment of a human patient comprising a composition comprising

• a poorly soluble drug which is aripiprazole or a salt thereof, or 7-[4-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)butoxy]-1H-quinolin-2-one or a salt thereof,
• water, and
• a suspending agent comprising polyvinylpyrrolidone, polyethylene glycol, and carboxymethyl cellulose or a salt thereof,
• wherein the poorly soluble drug has a mean primary particle diameter of 1 to 10 μm and is contained in a concentration of 300 mg/mL,
• K value of polyvinylpyrrolidone is 17, and the concentration of polyvinylpyrrolidone is 4 mg/mL,
• the polyethylene glycol is polyethylene glycol 400, and the concentration of polyethylene glycol is 1 mg/mL, and
• the concentration of carboxymethyl cellulose or a salt thereof is 5 mg/mL,
• the preparation being in the form of a gel when allowed to stand, and changing to a sol when subjected to an impact, and
• the preparation being administered once per month.

A sustained release injectable preparation comprising a composition comprising

• a poorly soluble drug which is aripiprazole or a salt thereof, or 7-[4-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)butoxy]-1H-quinolin-2-one or a salt thereof,
• water, and
• a suspending agent comprising polyvinylpyrrolidone, polyethylene glycol, and carboxymethyl cellulose or a salt thereof,
• wherein the poorly soluble drug has a mean primary particle diameter of 4 to 30 μm and is contained in a concentration of 300 mg/mL,
• K value of polyvinylpyrrolidone is 17, and the concentration of polyvinylpyrrolidone is 4 mg/mL,
• the polyethylene glycol is polyethylene glycol 400, and the concentration of polyethylene glycol is 1 mg/mL, and
• the concentration of carboxymethyl cellulose or a salt thereof is 5 mg/mL,
• the preparation being in the form of a gel when allowed to stand, and changing to a sol when subjected to an impact, and
• the preparation being administered once every two to three months.